Aceclofenac Tablet (Sustained Release) 200 mg

Aceclofenac Tablet (Sustained Release) by Pristine Pharmaceuticals Ltd is a specialized NSAID formulation containing 200 mg of the generic drug Aceclofenac. Designed for prolonged action, this sustained-release tablet effectively manages inflammatory conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Priced at ৳6.00 per unit, it offers cost-effective therapy with a strip price of ৳60.00.

This drug inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis to alleviate pain and inflammation. The sustained-release mechanism ensures 24-hour relief with once-daily dosing. As part of the Tablet (Sustained Release) category, it improves patient compliance compared to immediate-release versions. Adults should take one 200 mg tablet daily, preferably after meals.

Key precautions include avoiding use during pregnancy/lactation and monitoring interactions with anticoagulants or diuretics. Common side effects like nausea or stomach discomfort are usually mild. Store tablets in dry, cool conditions as recommended by Pristine Pharmaceuticals Ltd.

Adults: 200 mg once daily (Sustained Release). Adjust dose in hepatic/renal impairment. Administer with or after food. Do not exceed 2 weeks without medical supervision. Learn about Sustained Release tablets.

Aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

Contraindicated in third trimester. Use in first/second trimester only if benefits outweigh risks. Avoid during lactation. Explore Aceclofenac details.

Monitor liver/kidney function in long-term use. Exercise caution in asthma, GI bleeding history. Avoid driving if dizziness occurs. Pristine Pharmaceuticals recommends regular check-ups.

Start with lowest effective dose in elderly. Contraindicated in severe renal impairment (GFR <30 mL/min). Reduce dose by 50% in hepatic cirrhosis. Pediatric safety not established.